Cannae CNNE Q1 2026 Disappoints EPS 070 Below 045 Views Endurance Technologies IPO Launches Key Details on Rs 1162 Crore Public Offering Flywire FLYW Q1 2026 Earnings Surprise EPS 010 Up Significant Galaxy Digital Secures New York BitLicense to Expand Institutional Crypto Services GLXY C4 Thera CCCC Tanks 204 as Market Conditions Worsen 20260521 Wall Street Ends Higher as Mideast Peace Hopes Boost Sentiment Apogee APOG Stock Jumps 297 Approaching 3603 20260520 Lake LKSPR Slides 675 as Selling Pressure Mounts 20260520 Tech Media and Telecom Roundup Market Talks Highlight DeepSeek SoFi Amid Sector Movements Alternative Asset Managers Target SME Stocks for Migration Windfalls Amid Mainboard Stagnation Wealth Concealment The Emotional Toll of Hiding Financial Success Canadian Regulator Triples Streaming Giants Contribution to Canadian Content to 15 AkzoNobel Shares Surge After Rejecting 73Share Joint Bid from Nippon Paint and SherwinWilliams South Korea Deputy PM Calls for Public Benefit from AI Wealth Amid Samsung Labor Tensions CATY Q1 2026 Earnings Strong EPS Beat as Cathay General Bancorp Delivers 2275 Surprise Allot Ltd ALLT Q1 2026 Earnings EPS Surprise Highlights Cost Discipline Amidst Transition NGNE Q1 2026 Earnings EPS Falls Short of Consensus as PreRevenue Biotech Maintains RD Focus Red Violet RDVT Q1 2026 Earnings Strong EPS Beat Drives Stock Higher Arrive AI Inc ARAI Q1 2026 Earnings Narrowing Losses Beat Expectations but No Revenue Progress Weighs on Sentiment HS2 Cost Could Surge to 1027bn as Project Reset Slashes Speed Targets Ghost Brokers Target Young Drivers With Fake Car Insurance Scams on Social Media Traders Raise Odds of Fed Rate Hike by July 2027 as Inflation Concerns Persist SHG Q4 2025 Earnings EPS Misses Estimates on Challenging Conditions Magnera Corporation MAGN Q1 2026 Earnings EPS Misses Estimates by Wide Margin Amid Challenging Conditions Gyre Therapeutics GYRE Stock Analysis Falls 319 Watching 576 20260520 Artificial Intelligence Reshapes Quarterly Earnings Landscape A Broad Perspective Day One Biopharmaceuticals DAWN Q4 2025 Earnings EPS Miss Reflects RD Spend Amid PreRevenue Status